These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11078982)

  • 1. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study.
    Jørgensen JO; Rosenfalck AM; Fisker S; Nyholm B; Fineman MS; Schmitz O; Madsbad S; Holst JJ; Christiansen JS
    Eur J Endocrinol; 2000 Nov; 143(5):593-9. PubMed ID: 11078982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
    Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
    Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expected values for gastrointestinal and pancreatic hormone concentrations in healthy volunteers in the fasting and postprandial state.
    Meek CL; Lewis HB; Burling K; Reimann F; Gribble F
    Ann Clin Biochem; 2021 Mar; 58(2):108-116. PubMed ID: 33175577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
    Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
    Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
    Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H
    Acta Diabetol; 1995 Oct; 32(3):165-9. PubMed ID: 8590785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses.
    Engelbrechtsen L; Mahendran Y; Jonsson A; Gjesing AP; Weeke PE; Jørgensen ME; Færch K; Witte DR; Holst JJ; Jørgensen T; Grarup N; Pedersen O; Vestergaard H; Torekov S; Kanters JK; Hansen T
    BMC Genet; 2018 Mar; 19(1):15. PubMed ID: 29548277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.
    Cypryk K; Vilsbøll T; Nadel I; Smyczyńska J; Holst JJ; Lewiński A
    Gynecol Endocrinol; 2007 Jan; 23(1):58-62. PubMed ID: 17484514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incessant increase curve during oral glucose tolerance tests in Chinese adults with type 2 diabetes and its association with gut hormone levels.
    Zhang D; Wen Z; Jiang T; Sun Y
    Peptides; 2021 Sep; 143():170595. PubMed ID: 34116121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
    Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
    Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin secretion in humans is under the influence of cannabinoid receptors.
    Chia CW; Carlson OD; Liu DD; González-Mariscal I; Santa-Cruz Calvo S; Egan JM
    Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E359-E366. PubMed ID: 28655715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity.
    Ranganath LR; Beety JM; Morgan LM
    Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.